Lv1
28 积分 2022-12-21 加入
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
10天前
已完结
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study
10天前
已完结
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
14天前
已完结
Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study
17天前
已完结
Compound EGFR mutations are predominantly PACC (P-loop and alpha-C helix compressing) mutations with increased responsiveness to second- vs third-generation tyrosine kinase inhibitors
3个月前
已关闭
KIR2DL5 Can Inhibit Human NK Cell Activation Via Recruitment of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP-2)
3个月前
已完结
KIR2DL5 Can Inhibit Human NK Cell Activation Via Recruitment of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP-2)
3个月前
已关闭
PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
3个月前
已完结
The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy
3个月前
已完结
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
5个月前
已完结
皖公网安备34019202002308
